This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Enhabit (EHAB) Stock Overview
Provides home health and hospice services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
EHAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Enhabit, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.80 |
| 52 Week High | US$14.22 |
| 52 Week Low | US$6.47 |
| Beta | 0.96 |
| 1 Month Change | 0.51% |
| 3 Month Change | 23.66% |
| 1 Year Change | 29.70% |
| 3 Year Change | 16.06% |
| 5 Year Change | n/a |
| Change since IPO | -44.80% |
Recent News & Updates
Narrative Update • Apr 24
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.Narrative Update • Apr 10
EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.Narrative Update • Mar 26
EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.Recent updates
Narrative Update • Apr 24
EHAB: Kinderhook Cash Offer And Deal Completion Will Shape Forward Risk Balance
Analysts have aligned Enhabit’s updated fair value estimate with the agreed Kinderhook Industries takeout price, trimming the target by $0.03 to $13.80 as they factor in the all cash $13.80 per share acquisition and modest tweaks to growth, margin and discount rate assumptions. Analyst Commentary Street research has largely converged around Enhabit’s agreed takeout price, with multiple firms resetting ratings and targets to align with the US$13.80 per share all cash offer from Kinderhook Industries.Narrative Update • Apr 10
EHAB: Cash Sale Terms And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have inched their average price target for Enhabit up by about $0.03 to roughly $13.83, reflecting recent research that aligns estimates with the agreed all cash acquisition price of $13.80 per share. Analyst Commentary Recent research on Enhabit has shifted quickly after the announced all cash acquisition at $13.80 per share, with most commentary now centered on how closely the stock aligns with the agreed deal value rather than on long term standalone upside.Narrative Update • Mar 26
EHAB: Kinderhook Cash Deal And Reimbursement Backdrop Will Shape Forward Risk Balance
Analysts have adjusted Enhabit’s price target to $13.80 per share, in line with the agreed all cash acquisition price from Kinderhook Industries. They cite the pending takeout and recent shifts in ratings to Hold, Neutral, Perform and Market Perform at multiple firms as the key drivers of this update.Narrative Update • Mar 10
EHAB: Kinderhook Cash Takeout And Sector Reimbursement Trends Will Shape Forward Risk Balance
The analyst price target for Enhabit has been adjusted from $13.08 to $13.80. Analysts cite the agreed all-cash acquisition by Kinderhook Industries at $13.80 per share as the primary reference point for the valuation.Seeking Alpha • Feb 25
Enhabit: Why This Healthcare Buyout Won't Raise FTC Alarms
Summary Enhabit Inc. is being acquired by Kinderhook Industries for $13.80 per share, an all-cash deal at an enterprise valuation of $1.1 billion. I see minimal antitrust risk, as Kinderhook lacks significant overlap in hospice care, making regulatory intervention unlikely. EHAB trades at a discount to peers due to higher debt and inconsistent profitability, but the acquisition premium reflects limited market optimism. With only a 1.8% spread to the deal price and limited upside, I rate EHAB a Hold pending deal completion. Read the full article on Seeking AlphaNarrative Update • Feb 24
EHAB: Takeout At 13.80 And Reimbursement Clarity Will Shape Forward Risk Balance
The analyst price target for Enhabit has been raised from $11.75 to $13.08. Analysts cited the agreed all-cash acquisition at $13.80 per share and related updates to assumed future P/E as the key drivers of the change.Narrative Update • Feb 08
EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Forward Risk Balance
Narrative Update on Enhabit The analyst price target for Enhabit has moved to $11.75. Analysts note that clearer home health reimbursement rules, an improved regulatory backdrop, and what they describe as a discounted valuation support a more constructive stance on the shares.Narrative Update • Jan 25
EHAB: Clearer Reimbursement And Mixed Ratings Will Shape Future Earnings Visibility
Narrative Update The analyst price target for Enhabit has shifted from $10.60 to $11.75, as analysts factor in an improved home health reimbursement backdrop, clearer earnings visibility, and reduced regulatory overhang reflected in recent upgrades and higher targets around $12. Analyst Commentary Recent research on Enhabit has turned more positive, with several firms lifting ratings and price targets to around US$12 as the regulatory picture for home health reimbursement becomes clearer.Narrative Update • Jan 10
EHAB: Final Rule Clarity And Mixed Ratings Will Shape Earnings Outlook
Analysts have lifted their price expectations for Enhabit, with our fair value estimate moving from US$9.38 to US$10.60. They point to greater earnings clarity following the final home health rule, a modest adjustment to discount rates and profit assumptions, and recent research that highlights both improving operations and what some see as a discounted valuation.Narrative Update • Aug 08
Aging Demographics Will Fuel US Home Care Expansion
Despite a notable improvement in net profit margin and a lower future P/E ratio, the consensus analyst price target for Enhabit has been reduced from $10.00 to $9.38. What's in the News Enhabit, Inc.Analysis Article • Jul 03
Enhabit, Inc. (NYSE:EHAB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Enhabit, Inc. ( NYSE:EHAB ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Jun 14
Enhabit (NYSE:EHAB) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Narrative • May 29
US Home Health Demand And Value-Based Care Will Create Future Opportunities
Structural trends and targeted expansion in underserved markets are driving sustained revenue growth and building a reliable recurring revenue base.Analysis Article • May 09
Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...Analysis Article • Apr 09
Enhabit, Inc.'s (NYSE:EHAB) Revenues Are Not Doing Enough For Some Investors
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Seeking Alpha • Feb 03
Enhabit: Healthcare Predictive Analytics, FCF, Very Undervalued
Summary EHAB's investments in healthcare predictive analytics, expected to grow at 23%-24% CAGR, could significantly boost future net income growth. Restructuring, activism, and strategic reviews are potential catalysts for stock price appreciation, enhancing financial flexibility from 2025 to 2030. Despite recent negative net income, EHAB's consistent positive cash flow and undervaluation indicate substantial upside potential in stock price. Valuation models suggest higher upside potential, with best case scenario implying a target price of $11-$12 per share. Read the full article on Seeking AlphaAnalysis Article • Dec 14
Is Enhabit (NYSE:EHAB) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Nov 07
Returns On Capital At Enhabit (NYSE:EHAB) Paint A Concerning Picture
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...Analysis Article • Jul 17
Is Enhabit (NYSE:EHAB) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Jul 15
Is Enhabit Dead? Not Quite Yet
Summary It is soon to be the last independent home health and hospice company. Scarcity value could drive interest from financial and strategic bidders. Shareholders have a slate of new directors to refresh the company. Read the full article on Seeking AlphaAnalysis Article • Jun 19
Enhabit (NYSE:EHAB) Could Be At Risk Of Shrinking As A Company
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...Analysis Article • May 10
An Intrinsic Calculation For Enhabit, Inc. (NYSE:EHAB) Suggests It's 42% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Enhabit fair value estimate is US$14.19 Enhabit is estimated...Analysis Article • Mar 09
Here's What Analysts Are Forecasting For Enhabit, Inc. (NYSE:EHAB) After Its Annual Results
It's been a pretty great week for Enhabit, Inc. ( NYSE:EHAB ) shareholders, with its shares surging 17% to US$10.34 in...Analysis Article • Mar 05
The Market Doesn't Like What It Sees From Enhabit, Inc.'s (NYSE:EHAB) Revenues Yet
You may think that with a price-to-sales (or "P/S") ratio of 0.4x Enhabit, Inc. ( NYSE:EHAB ) is a stock worth checking...Analysis Article • Feb 09
Enhabit (NYSE:EHAB) Could Be Struggling To Allocate Capital
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Shareholder Returns
| EHAB | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.07% | -0.4% | 1.1% |
| 1Y | 29.7% | 16.3% | 28.7% |
Return vs Industry: EHAB exceeded the US Healthcare industry which returned 19.6% over the past year.
Return vs Market: EHAB exceeded the US Market which returned 26.7% over the past year.
Price Volatility
| EHAB volatility | |
|---|---|
| EHAB Average Weekly Movement | 6.6% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EHAB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EHAB's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10,800 | Barb Jacobsmeyer | www.ehab.com |
Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer’s disease, low vision, spinal stenosis, Parkinson’s disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient’s health-related problems.
Enhabit, Inc. Fundamentals Summary
| EHAB fundamental statistics | |
|---|---|
| Market cap | US$706.91m |
| Earnings (TTM) | -US$3.20m |
| Revenue (TTM) | US$1.06b |
0.7x
P/S Ratio-220.9x
P/E RatioIs EHAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EHAB income statement (TTM) | |
|---|---|
| Revenue | US$1.06b |
| Cost of Revenue | US$544.20m |
| Gross Profit | US$520.70m |
| Other Expenses | US$523.90m |
| Earnings | -US$3.20m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.062 |
| Gross Margin | 48.90% |
| Net Profit Margin | -0.30% |
| Debt/Equity Ratio | 72.7% |
How did EHAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/16 19:15 |
| End of Day Share Price | 2026/05/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enhabit, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joanna Sylvia Gajuk | BofA Global Research |
| Jason Cassorla | Citigroup Inc |
| Jamie Perse | Goldman Sachs |